Table 1 Analysis of Src-pY416 in primary epithelial ovarian cancer specimens

From: Targeting Src in endometriosis-associated ovarian cancer

 

Negative, N (%)

Positive, N (%)

P-value

Stage

 Stage 1

49 (68)

23 (32)

 

 Stage 2

21 (66)

11 (34)

 

 Stage 3

144 (61)

91 (39)

 

 Stage 4

28 (74)

10 (26)

0.415

 Stage 1/2

70 (67)

34 (33)

 

 Stage 3/4

172 (63)

101 (37)

0.510

Grade

 FIGO1/2

26 (67)

13 (33)

 

 FIGO3

217 (64)

124 (36)

0.844

Histology

 Serous

166 (66)

86 (34)

 

 Clear cell

17 (41)

24 (59)

 

 Mucinous

17 (81)

4 (19)

 

 Endometrioid

22 (61)

14 (39)

 

 Mixed

10 (63)

6 (37)

0.017

 EAOCa

39 (51)

38 (49)

 

 Non-EAOC

183 (67)

90 (33)

0.011

 Serous

166 (66)

86 (34)

 

 Non-Serous

56 (57)

42 (43)

0.139

Optimal debulking

 No

102 (63)

61 (37)

 

 Yes

138 (65)

74 (35)

0.6929

Recurrence

 No

73 (66)

38 (34)

 

 Yes

87 (63)

64 (37)

0.2006

  1. Abbreviation: EAOC, endometriosis-associated ovarian cancer.
  2. 381 specimens were analyzed by immunohistochemical staining for phospho-Src (Tyr416). P-values represent results from simple linear regression. Percentages denote the percent of positive and negative tumors within each group, which is indicated by the row name.
  3. aClear cell and endometrioid compared with serous and mucinous; mixed tumors were excluded.
Back to article page